{"id":"W4220742828","doi":"10.1007/s40120-022-00341-z","title":"COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Sanofi Genzyme; Greenwich Biosciences; EMD Serono; National Institutes of Health; Genentech; Multiple Sclerosis Society; International Progressive MS Alliance; Race to Erase MS; TG Therapeutics; Bristol-Myers Squibb; University of Miami; Biogen; Celgene; Alexion Pharmaceuticals; U.S. Department of Defense; Conrad N. Hilton Foundation; Sanofi; National Multiple Sclerosis Society; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries","keywords":"Medicine; Vaccination; Ofatumumab; Coronavirus disease 2019 (COVID-19); Multiple sclerosis; Internal medicine; Pandemic; Pediatrics; Disease; Immunology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002281427,0.0001347024,0.0002950433,0.0001930049,0.0003381667,0.00001088448,0.000043594,0.00004304183,0.0001177569],"category_scores_gemma":[0.0001554663,0.00009117575,0.00001624449,0.0002598707,0.00009465084,0.00005573078,0.00005764981,0.0003396073,3.882879e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004329311,"about_ca_system_score_gemma":0.00007638957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000511809,"about_ca_topic_score_gemma":0.001032511,"domain_scores_codex":[0.9989036,0.000229381,0.0001213243,0.0003270206,0.0001944206,0.0002242972],"domain_scores_gemma":[0.9992148,0.0004360942,0.00005004182,0.0001452637,0.0000303581,0.0001234187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005895737,0.0001631285,0.9834507,0.00001912572,0.00006847023,0.00003761388,0.001232072,0.00005855069,0.001451981,0.00001277366,0.00006778776,0.007542024],"study_design_scores_gemma":[0.01393982,0.002874609,0.9808202,0.000005659193,0.00001226442,0.00007899446,0.0001830473,0.0007119575,0.00009046743,0.00001612604,0.001181259,0.00008552651],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894118,0.0007139603,0.00001616004,0.009100503,0.00001783007,0.0005786452,0.000007918982,0.0000459454,0.000107259],"genre_scores_gemma":[0.9937291,0.002236385,0.00006404223,0.003690565,0.000008912034,0.0001735378,0.00001229088,0.0000185701,0.00006660559],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008044087,"threshold_uncertainty_score":0.3718039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05366258251714152,"score_gpt":0.3011824989109759,"score_spread":0.2475199163938344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}